

## LABScreen™



**Catalog # (See LABScreen Reference Table for product identification.)**  
For In Vitro Diagnostic Use.

### INTENDED USE



LABScreen products are intended for use in detection of HLA antibody using flow cytometric technology

### SUMMARY AND EXPLANATION

LABScreen products use microbeads coated with purified Class I or Class II HLA antigens and pre-optimized reagents for the detection of Class I or Class II HLA antibodies in human sera. LABScreen products utilize the LABScan™ 100 (Luminex® 100/200) or LABScan3D™ (Luminex® FLEXMAP 3D®) for analysis of up to 100 or 500 bead regions, respectively, in a single test.

The Mixed assay detects the presence of antibody to Class I and/or Class II HLA antigens. The PRA tests can detect antibodies and their specificities against the HLA antigens in each LABScreen panel. The Single Antigen assay allows confirmation of antibody specificity suggested by a previous PRA test, while individual Singles beads are used to focus on reactions against one or a few antigens, e.g. to compare reactivity of different serum samples from the same individual. A negative control serum is used to establish the background value for each bead in a test batch.

### PRINCIPLE(S)

Test serum is incubated with LABScreen beads. Any HLA antibodies present in the test serum bind to the antigens on the beads and then are labeled with R-Phycoerythrin (PE)-conjugated goat anti-human IgG. The LABScan™ 100 or LABScan3D™ flow analyzer(s) simultaneously detects the fluorescent emission of PE and a dye signature from each bead, allowing almost real-time data acquisition. To assign PRA and HLA specificity, the reaction pattern of the test serum is compared to the lot-specific worksheet defining the antigen array.

### REAGENTS

#### A. Identification

See LABScreen Reference Table for product description.



#### B. Warning or Caution



- Warning:** LABScreen PRA test reagents contain 0.1% sodium azide (NaN<sub>3</sub>) as a preservative. Under acidic conditions, sodium azide yields hydrazoic acid, an extremely toxic compound. Dilute reagents containing sodium azide in running water before discarding, to avoid deposits in plumbing where explosive conditions may develop. (Refer to Material Safety Data Sheet for detail.)
- Warning:** All blood products should be treated as potentially infectious. Source material from which this product was derived was found negative when tested in accordance with current FDA required tests. No known test methods can offer assurance that products derived from human blood will not transmit infectious agents.
- Caution:** For manual flicking of trays, use a quick downward arm motion without wrist movement to prevent repetitive motion effects.





4. Refer to the Material Safety Data Sheet for detailed information.

C. Preparing Reagents for Use

1. See Directions for Use, below.
2. If buffer salts have precipitated out of solution during shipment or storage, re-dissolve by gently warming before preparing working dilution.



D. Storage Instructions

1. LABScreen products are shipped to the end user on dry ice. The entire package may be stored in a freezer at -65° C or below until first use, up to the labeled expiration date.
2. Once beads are thawed, DO NOT REFREEZE. Store at 2 - 8° C for up to three months or until the expiration date (if earlier).
3. After first use, store wash buffer at 2 - 8°C for up to three months or until the expiration date, if earlier.

E. Purification or Treatment Required for Use

See Directions for Use, below.

F. Instability Indications

None

## INSTRUMENT REQUIREMENTS

### A. Required Equipment

- LABScan™ 100 flow analyzer (Luminex® 100/200) with Luminex® XY platform (for automated 96-sample data acquisition) and sheath fluid delivery system (OLI Cat. # LABSCNXS3) OR LABScan3D™ flow analyzer (Luminex® FLEXMAP 3D®) with XY platform and sheath fluid delivery system (OLI Cat. # LABSCNXS4)
- Centrifuge
- Rotor for 1.5 ml microcentrifuge tube (9,300 g), or a swinging bucket rotor for 96-well microplate (1,300 g)
- Vortex mixer
- Plate shaker or rotating platform

#### For Filter Plate Option:

- Vacuum manifold, 96-well (Millipore Cat. # MAVM0960R or equivalent)
- Vacuum pump with a pressure less than 100 mm Hg
- Plate shaker or rotating platform

### B. Equipment Calibration

Follow manufacturer's instructions for calibration of the LABScan™ 100 or LABScan3D™ flow analyzer.

### C. Recommended Software

HLA Fusion™ (OLI Cat. # FUSPGR)

## SPECIMEN COLLECTION AND PREPARATION

- Unopened blood specimens may be kept at room temperature up to 4 days. Separated serum (from clotted samples) or plasma (in ACD or K-EDTA) may be refrigerated up to 7 days, or aliquots may be frozen at -20°C or below and thawed just before the assay. Aggregates should be removed from the test serum/plasma by centrifugation (8,000 – 10,000 g for 10 minutes) or filtration (0.2 µm) prior to testing. Any aggregates or contamination of the sample may generate invalid results.
- Test serum or plasma should not be heat inactivated, because it may give a high background in the test.

- Undiluted serum or plasma is generally used for the test. However, if a high background serum sample is diluted for this assay, the negative control serum should be tested at the same dilution.

## PROCEDURE

### A. Materials Provided

1. See the LABScreen Reference Table (LS-RFTB-PI-XX-00) in Product Documentation on the One Lambda, Inc. web site for a list of materials provided for each product.
2. The volumes provided exceed the amount required for testing by a small amount to allow for pipetting losses.

### B. Materials Required, But Not Provided

1. PE-Conjugated Goat Anti-Human IgG (OLI Cat. # LS-AB2)
2. PBS, filtered [USA Scientific Cat. # 9242 (500 ml 10X) or equivalent]
3. 1.5 ml microcentrifuge tube (USA Scientific Cat. # 1415-2500 or equivalent)
4. Pipette tips (Rainin GPS)
5. Negative Control Serum, containing no HLA antibody when tested by LABScreen method (OLI Cat. # LS-NC or equivalent)

#### If the test is performed in a 96-well microplate:

1. 96-well microplate, 250 µl, non-treated surface (Whatman Cat. # 7701-3250 or equivalent)
2. Tray seal (OLI Cat. # SSPSEA300 or equivalent)

#### For the Filter Plate option:

1. Filter plate (Multiscreen-BV, Millipore Cat. No. MABVN1250 or equivalent)

### C. Directions for Use

#### Notes:

- Take special care in the aliquoting process. Failure to follow the steps described below may result in reagent loss.
- Sections A through C indicate the volumes of reagents needed for testing a single bead group. If you are running a combined test, see Section D before proceeding.
- Turn on the LABScan 100™ or LABScan3D™ flow analyzer at least 30 minutes before starting the assay.
- Create a filename and sample code sheet for each test tray.

#### I. For each test batch, test a negative control serum (e.g. OLI Cat. # LS-NC or equivalent) to establish background values. To complete the test in a 1.5 ml microcentrifuge tube

1. Mix the LABScreen beads well by gently vortexing or pipetting up and down several times prior to use.
2. Incubate 5 µl of LABScreen beads with 20 µl of test serum in a 1.5 ml micro-centrifuge tube for 30 minutes, in the dark at 20 - 25° C with gentle shaking.
3. Dilute 10X wash buffer (OLI Cat. # LSPWABUF) in distilled water to make a 1X solution.
4. Add 1 ml of 1X wash buffer to each bead/serum solution tube and vortex. Centrifuge at 9,300 g for 2 minutes. Aspirate and discard the supernatant.
5. Repeat Step 4 twice.
6. Dilute 1 µl per test of 100X PE-conjugated anti-human IgG (OLI Cat. # LS-AB2) with 99 µl of 1X wash buffer to make a 1X solution.
7. Add 100 µl of 1X PE-conjugated anti-human IgG to each tube. Vortex and then incubate in the dark for 30 minutes at 20 - 25° C with gentle shaking.

- Repeat Step 4 twice.
- Add 80 µl 1X PBS to each tube. Proceed to data acquisition and analysis, or store tray at 2 - 8° C in the dark for up to 24 hours before analysis.

## II. To complete the test in a 96-well plate

**Caution:** Seal the 96-well tray carefully and completely to prevent well-to-well sample contamination by pressing the seal against each rim of the 96 wells. Do not re-use tray seals. Use a fresh seal for each step that requires application of a tray seal.

- Mix the LABScreen beads well by gently vortexing or pipetting up and down several times prior to use.
- Incubate 5 µl of LABScreen beads with 20 µl of test serum in each well of a 96-well plate for 30 minutes, in the dark at 20 - 25° C with gentle shaking.
- Dilute 10X wash buffer (Cat. # LSPWABUF) in distilled water to make a 1X wash solution.
- After incubation, add 150 µl of 1X wash buffer to each well of the plate. Cover with tray seal (OLI Cat. # SSPSEA300 or equivalent) and vortex. Centrifuge at 1,300 g for 5 minutes.
- Remove wash buffer from wells of plate by flicking or with vacuum aspiration.
- Add 200 µl of 1X wash buffer to each well of the plate. Cover with a new tray seal and vortex. Centrifuge at 1,300 g for 5 minutes.
- Remove supernatant from wells of plate by flicking or with vacuum aspiration.
- Repeat Steps 6 and 7.
- Dilute 1 µl per test of 100X PE-conjugated anti-human IgG (OLI Cat. # LS-AB2) with 99 µl of 1X wash buffer to make a 1X solution.
- Add 100 µl of 1X PE-conjugated anti-human IgG to each well. Cover with tray seal and vortex. Incubate in the dark for 30 minutes at 20 - 25° C with gentle shaking.
- Centrifuge at 1,300 g for 5 minutes.
- Remove supernatant from wells of plate by flicking or with vacuum aspiration.
- Repeat Steps 6 and 7 twice.
- Add 80 µl 1X PBS to each well. Cover with a new tray seal and vortex. Proceed to data acquisition and analysis, or store tray at 2 - 8° C in the dark for up to 24 hours before analysis.

## III. To complete the test in a 96-well filter plate

- Mix the LABScreen beads well by gently vortexing or pipetting up and down several times prior to use.
- Dilute 10X wash buffer (OLI Cat. # LSPWABUF) in distilled water to make a 1X solution (approximately 3.2 ml/tray/wash).
- Cover any wells of the plate that will remain unused during the test with a tray seal to assure that the unused wells remain dry. Pre-wet filters in the filter plate by dispensing 300 µl wash buffer into only those wells that will be used for the assay.
- Incubate the plate for 10 minutes on a platform plate shaker at low speed.
- Aspirate all wash buffers from the wells using a Millipore vacuum manifold. Do not exceed 100 mm Hg vacuum pressure!
- Add 5 µl of LABScreen beads and 20 µl of test serum per test well.  
**Note:** During bead and sample dispensing steps, press pipette tip gently against filter plate well to avoid filter rupture.
- Incubate the plate in the dark for 30 minutes at 20 - 25° C with gentle shaking.
- Add 175 µl wash buffer per well.

9. Turn on vacuum pump. Press the plate firmly on the vacuum manifold. Make sure liquid drains out slowly. Make sure all liquid has drained from the wells before proceeding.



**Caution:** Do not exceed 100 mm Hg vacuum pressure. A rapid vacuum will cause loss of beads due to be entrapment in the pores of the filter paper.

10. Repeat Steps 8 and 9, above, four times.
11. Add 100 µl of 1X PE-conjugated anti-human IgG to each well.
12. Incubate in the dark for 30 minutes at 20 - 25° C with gentle shaking.
13. Repeat Steps 8 and 9 five times.
14. Add 80 µl of 1X PBS to each well.
15. Read sample on the LABScan 100™ or LABScan3D™ flow analyzer, adjusting probe height if necessary.

#### IV. Combined tests

Any of the above protocols can be used for a combined test of certain LABScreen products.

- For acceptable lot combinations of LS12PRA see [www.onelambda.com](http://www.onelambda.com) (Antibody Detection>LABScreen>LABScreen PRA/ Product Documentation: LABScreen Bead Combo – Multiple IDs DataSheet).
  - Do not combine LABScreen Single Antigen Class I Combi and Class II panels (bead IDs would overlap).
1. Mix equal volumes of beads. Then dispense the appropriate aggregate amount (10 or 15 µl) of bead mixture per test.
  2. Bead combinations and amounts to dispense are listed in the table below.

Catalog ID	Bead volume per Test	Control (NC/PC) Beads	Test Serum per Test
<b>LS12PRA (CI and CII beads)</b>	5 µl + 5 µl	Included	40 µl
<b>LS1A04</b>	5 µl	Included	20 µl

## RESULTS

### A. Data Acquisition

1. Set up the LABScan 100™ or LABScan3D™ flow analyzer for sample acquisition and calibration according to the Luminex User's Manual.<sup>1</sup>
2. Choose a template according to product kit catalog ID and lot number.
  - a. Acquisition templates are available from OLI by CD or via our download website.
  - b. To create your own acquisition template, follow instructions in the Acquisition chapter of the Luminex User's Manual.
  - c. Luminex software versions - LABScan 100 (IS 2.2/2.3, xPONENT 3.1, or xPONENT 4.2); LABScan 3D (xPONENT 4.0 or xPONENT 4.2) must be used.
3. Create a file name for the samples to be run.
4. Make sure all the template settings are correct. Template specifications are:
  - a. Set sample volume to 50 µl.
  - b. Set sample time-out to 80 seconds.
  - c. Set doublet discriminator gate to 8,000 (low limit) and 16,000 (high limit).
  - d. Set number and ID of beads selected according to the product-specific worksheet provided with the product.
  - e. Set minimum events collected to 100 per bead.

5. Enter the sample IDs (if the same sample is tested more than once, assign a different ID).
6. Load the plate onto the XY platform and fill the reservoir with sheath fluid.
7. Click the START button to initiate the session. After the samples have finished running, save the data output in a .csv file.
8. Wash the machine twice with sheath fluid at the end of the session.

**B. Data Analysis**

1. The reactivity of a test sample is calculated from the “raw” fluorescence values recorded by the LABScan device (.csv file) for each HLA coated bead.
2. Calculate anti-HLA serum reactivity by correcting for non-specific binding to the negative control bead and background values (obtained by testing with a negative control serum (OLI Cat. # LS-NC) to determine the normalized background ratio (NBG ratio). See Calculations, below.
3. For LABScreen PRA or LABScreen Single Antigen, the normalized fluorescent value for each HLA coated bead equals the value of that bead divided by the value of the NC bead. (For LABScreen Mixed, the normalized fluorescent signal equals the value of the Class I or Class II coated bead minus the value of the NC bead.)

**Note:** The fluorescent signal (value) can be either the trimmed mean or median value.

**C. Calculations**

1. The abbreviations used in this section are defined below:

<b>NBG ratio</b>	Normalized Background ratio used to assign strength of each anti-HLA reaction
<b>S#N</b>	Sample-specific fluorescent value for bead #N
<b>SNC bead</b>	Sample-specific fluorescent value for Negative Control bead
<b>BG#N</b>	Background NC Serum fluorescent value for bead #N
<b>BGNC bead</b>	Background NC Serum fluorescent value for Negative Control bead
<b>NC Serum</b>	Negative Control Serum (OLI Cat. # LS-NC) validated for a given lot of LABScreen beads

2. For LABScreen PRA or LABScreen Single Antigen:

$$\text{NBG ratio} = \frac{\text{S\#N} / \text{SNC bead}}{\text{BG\#N} / \text{BGNC bead}}$$

For LABScreen Mixed:

$$\text{NBG ratio} = \frac{\text{S\#N} - \text{SNC bead}}{\text{BG\#N} - \text{BGNC bead}}$$

**Note:** If (BG#N-BGNC bead) <50 then use 50 as a default threshold value.

**D. Determination of Positive/Negative Cut-Off**

1. For LABScreen PRA and LABScreen Mixed:
  - a. Select the NBG ratio that gives a significant shift over background fluorescent value when the background value is obtained using the negative control serum in 3 - 5 replicate tests. If you prefer, test 5 - 10 serum samples from non-transfused, non-transplanted male donors to obtain an average background value.
  - b. Validate the cut-off using 5 - 10 reference alloserum samples with defined HLA antibody specificity. The NGB ratio values for expected positive antigen reactions should be above the cut-off.
  - c. Additional positive/negative reactions may be noted. If necessary, adjust the LABScreen assay cut-off to match the sensitivity of a previously accepted antibody detection assay.
  - d. For high PRA serum, the patient’s own antigen(s) may show weak positive reactions. For such cases, the fluorescence value for the patient’s own antigen may be used as the cut-off.
2. For LABScreen Single Antigen:
  - a. Test negative control serum or several negative serum samples (see 1a, above).
  - b. Define working range:  
 Working Range = NBG ratio maximum - NBG ratio minimum

- c. Define cut-off points within the working range:  
Relative NBG ratio cut-off = X% (working range) + NBG ratio minimum, where X% = user-defined percent cut-off point within the working range for negative (1), gray area(2), weak positive (4) and strong positive (8).
  - d. Set criteria to define positive vs. negative reactions, for example:
    - (1) If [NBG ratio max/NBG ratio min] >8, apply the calculation in 2c.
    - (2) If [NBG ratio max/NBG ratio min] <8 AND
      - (a) NBG ratio max >5, then NBG ratio min should be adjusted to one half of the NBG ratio max and the relative NBG ratio cut-off should be re-computed (as in 2c) based on the adjusted NBG ratio min. The reaction is then scored as above.
      - (b) NBG ratio max <5, then the reaction of the test serum with that bead is negative. Assign a score of "1".
  - e. Test several reference allosera as in 1b above, using the relative NBG ratio to validate the cut-off.
    - (1) Establish a strong and weak reactivity cut-off based on the performance of the reference allosera, relative to an established assay.
    - (2) It may be helpful to plot the NBG ratio values in a histogram for visualization of the HLA reactivity pattern of each serum.
3. Higher or lower sensitivities can be obtained by adjusting the cut-off.
  4. Optional analysis – HLA Fusion™ software.

## LIMITATIONS OF THE PROCEDURE

- Sera or plasma samples that contain contaminants or aggregates may clog the LABScan flow analyzer and generate inaccurate data. Aggregates in the test specimen should be removed by centrifugation or filtering the serum prior to testing.
- The presence of IgG-IgM immune complex may cause inhibition in some patient samples. Samples should be treated to reduce this presence according to the protocols determined by the laboratory, however, samples should not be heat treated as they may cause non-specific background – please reference bibliography section for more information.<sup>7,8,9,10</sup>
- Ambient temperature may affect LABScan 100™ and LABScan3D™ performance. If the ambient temperature changes, the machine may need to be re-calibrated. Consult the manufacturer's manual for more information.
- The LABScan 100™ and LABScan3D™ flow analyzer must be properly calibrated and maintained. If insufficiently flushed, aggregates of the sample may cause the machine to clog and generate invalid data.
- Assignment of antibody specificity is limited to the HLA antigens presented in each bead panel (see lot-specific worksheet).
- The bead region used for each antigen and the antigen composition of the panel may change from lot-to-lot of product (see the lot specific worksheet).
- Because of the complexity of the HLA allelic definitions, a certified HLA technician or specialist should review and interpret the data, and assign the HLA typing.
- This test must not be used as the sole basis for making a clinical decision.

## EXPECTED VALUES

### A. LABScreen PRA Class I or Class II

- The reactivity strength of a test serum to each bead can be compared to distinguish the strong positive, weak positive and negative reactions. Reactivity ratios can be ranked within different ranges, if a scoring system is desired.
- Our data show NBG ratios > 1.5 in the LABScreen PRA test (using the LABScan™ 100) correlate well with positive reactions in the FlowPRA test.
- For calculation of percent PRA (Panel Reactive Antibody), divide the number of positive reactions by the number of valid reactions for that test serum.
- To determine the specificity of HLA antibody, enter the reaction score into the lot specific Worksheet to analyze the reaction pattern.

#### **B. LABScreen Mixed**

- Score HLA Class I and Class II reactions separately, according to reactivity strength of the serum for each bead set.
- If anyone bead in the mixed assay is positive, then the result should be assigned as positive.
- Our data show that NBG ratios >2.2 in the LABScreen Mixed test (using the LABScan™ 100) correlate well with positive reactions in LAT™ Mixed.

#### **C. LABScreen Single Antigen**

- Allosera may produce signal/background ratios that are much higher than those obtained in the PRA assay. Establishing the assay cut-off(s) using the relative NBG ratio is one way of normalizing the data (see Results, Section D-2c).
- Our data show that a positive/negative cut-off or relative NBG ratio >15% of the working range NBG ratio calculated for each test serum (using the LABScan™ 100) will give results comparable to the LABScreen PRA assay.

#### **D. General Guidelines**

- Each bead count should be over 50. A lower bead count may be due to sample loss during the wash steps. It could also be due to improper calibration or clogging of the LABScan™ 100 or LABScan3D™ flow analyzer, or by photo-bleached beads that dropped out from the mapped region.
- Signal values are the fluorescence intensity of each bead set vs. the test serum. A negative control serum should be tested with the same batch of samples to establish the background value(s) for that test run.
- Negative Control Serum (OLI Cat. # LS-NC or equivalent) is recommended. Using any other negative control serum may require adjustment of cut-off values.
- Negative Control Beads (Ag ID = NC) are not coated with HLA antigen. The fluorescence value may vary among different sera due to non-specific binding of the sera or to insufficient washing. The NC value is usually less than 500 except for serum samples with a high background. It should always be lower than 1500 and less than or equal to half of the PC value.
- Positive Control Beads are coated with purified human IgG, which should bind to the secondary antibody to produce a positive signal. The PC value should be over 500 and at least twice the NC value.

#### **E. Validation of the Assay**

- The cut-off value of signal to background should be validated if a new negative control serum is used.
- For a given serum, the value for PC/NC should be greater than 2. A lower value may be due to an extremely high NC bead background value for the test serum, a high HLA bead signal for the NS control, or a low signal from the secondary antibody or the LABScan™ 100 and LABScan3D™ flow analyzer. In this case, the data may have to be confirmed.
- Each user should evaluate the performance of the assay in their laboratory to validate the cut-off value(s) selected.
- Plasma samples may give lower FI or higher background values than serum. The user may wish to normalize the data if comparing results between sera and plasma samples (see Reference 5) for the same or different test subjects.

**SPECIFIC PERFORMANCE CHARACTERISTICS**

- A. Using the assay cut-offs referenced under Expected Values, above, LABScreen assays have given results comparable to the results of the One Lambda FlowPRA® and LAT™ assays. However, HLA antibody patterns may be quite complex. A given test sample may contain several HLA Class I and Class II antibody specificities, each with a different avidity; however, not all specificities will be recognized in assays with lesser sensitivity. Therefore, each laboratory should establish and validate the assay cut-offs for their own use based on their expertise in recognizing HLA CREG patterns and an evaluation of the assay performance using HLA allosera with defined specificities.
- B. Comparison of serum vs. plasma for 1,000 blood donors in the NIH/NIH REIDS-II study (5) showed good correlation within the working range of the assay. For anti-HLA CI and CII antibodies the R2 values were 0.88 and 0.91, respectively. However, the NBG ratio was generally 1.3-fold higher for serum samples.
- C. If high background is seen, this may indicate improper washing during the test protocol. High negative control background may cause inaccurate normalized MFI values.
- D. Clinical performance testing was conducted for LABScreen products at three different clinical sites, using 240 random samples – See Table A. Clinical Performance.
- E. Clinical reproducibility testing was conducted for LABScreen products at three different clinical sites using 16 (LS1PRA, LS2PRA, LS1A04) and 32 (LSM12) samples, consisting of 10 runs each, in triplicate – see Table B. Clinical Reproducibility.
- F. Clinical testing used a default cut off value, with scores of >4 were considered positive.

**Table A - Clinical Performance**

LABScan 100	LABScan 3D			
	+	-		
+	573	11	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
-	4	119		
Undefined		40		
Total Defined		707		
	Positive Agreement	Negative Agreement	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
Point estimate	98%	97%	98%	93%
One-sided 95% lower confidence limit	97%	93%	97%	91%

LABScan 100	LABScan 3D			
	+	-		
+	939	57	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
-	187	7781		
Total		8964		
	Positive Agreement	Negative Agreement	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
Point estimate	94%	98%	98%	97%
One-sided 95% lower confidence limit	93%	97%	97%	97%

LABScan 100	LABScan 3D			
	+	-		
+	2060	260	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
-	446	16905		
Total		19671		
	Positive Agreement	Negative Agreement	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
Point estimate	89%	97%	96%	96%
One-sided 95% lower confidence limit	88%	96%	96%	96%

LABScan 100	LABScan 3D			
	+	-		
+	3245	214	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
-	682	12062		
Total		16203		
	Positive Agreement	Negative Agreement	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
Point estimate	94%	95%	94%	94%
One-sided 95% lower confidence limit	93%	94%	94%	94%

**Table B - Clinical Reproducibility**

LSM12	Overall Agreement (excluding undefined)	Overall Agreement (including undefined)
Point estimate	98%	93%
One-sided 95% lower confidence limit	97%	93%

LS1PRA	Overall Agreement	LS2PRA	Overall Agreement	LS1A04	Overall Agreement
Point estimate	99%	Point estimate	99%	Point estimate	98%
One-sided 95% lower confidence limit	99%	One-sided 95% lower confidence limit	99%	One-sided 95% lower confidence limit	98%

**BIBLIOGRAPHY**

1. Luminex 100 or 200 User's Manual, Luminex Corporation, PN 89-00002-00-005 or PN 89-00002-00-109
2. Luminex® FLEXMAP 3D® Hardware User Manual, Luminex Corporation PN 89-00002-00-187 Rev. B
3. R Pei, J-H Lee, T Chen, S Rojo, and PI Terasaki. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Human Immunology 60, 1293-1302 (1999)
4. R Pei, G Wang, C Tarsitani, S Rojo, T Chen, S Takemura, A Liu, and J-H Lee. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Human Immunology 59, 313-322 (1998)
5. RA Bray, DA Sinclair, L Wimoth-Hosey, C Lyons, P Chapman and J Holcomb. Significance of the flow cytometric PRA in the evaluation of patients awaiting renal transplantation. Department of Pathology, Emory University, Atlanta, GA. ASHI abstract (1998)
6. PJ Norris, J-H Lee, DM Carrick, JL Gottschall, M Lebedeva, BR De Castro, SH Kleinman, and MP Busch. Long-term in vitro reactivity for HLA antibodies and comparison of detection using serum vs. plasma. Transfusion 49(2), 243-251 (2008)
7. Tambur et al., Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information, Am J Transplant. 2015; 15: 2421-30
8. J. Visentin et al., Deciphering Complement Interference in Anti-Human Leukocyte Antigen Antibody Detection With Flow Beads Assays, Transplantation 2014;98: 625-631
9. G. Guidicelli et al., The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients, Transplant Immunology 2013; 29: 17-21
10. J. Visentin et al., Deciphering IgM interference in IgG anti-HLA antibody detection with flow beads assays, Hum. Immunol. 2016, <http://dx.doi.org/10.1016/j.humimm.2016.02.008>

**TRADEMARKS AND DISCLAIMERS**

™ LABScan, LABScan3D, HLA Fusion, Lambda Antigen Tray and LAT are trademarks of One Lambda, Inc.

™ FlowPRA and LABScreen are registered trademarks of One Lambda, Inc.

® Luminex and FLEXMAP 3D are registered trademarks of Luminex Corporation.

All One Lambda products are designed to assist personnel experienced in HLA analysis by suggesting typing results or antibody assignments. All test results must be carefully reviewed by such qualified personnel to assure correctness.

**EUROPEAN AUTHORIZED REPRESENTATIVE**

**EC REP** MDSS GmbH, Schiffgraben 41, 30175, Hannover, Germany

**EXPLANATION OF SYMBOLS**

Symbol	Description
	Catalog number
	In vitro diagnostic medical device
	Consult instructions for use
	Caution, consult accompanying documents
	Biological risks
	Temperature limitation
	Manufacturer
	Authorized representative in the European Community

**REVISION HISTORY**

Revision	Date	Revision Description
22	2014/08	Addition of xPONENT version 4.2 for LABScan 3D. Remove all reference and instructions for LABScreen Singles due to product discontinuation. Transferred to new PI template
23	2015/08	Remove xPONENT 4.0. Remove ® and Add Trademark ™. Transfer to new PI template.
24	2015/11	add language to our limitations section regarding sample preparation
25	2016/08	Addition of xPONENT version 4.2 for the LABScan 100
26	2016/10	Update to product limitation sections and bibliography section.



\*0197 Applies to Annex II List B products only.